Therapeutic Antibody Discovery in Infectious Diseases Using Single-Cell Analysis

Adv Exp Med Biol. 2018:1068:89-102. doi: 10.1007/978-981-13-0502-3_8.

Abstract

Since the discovery of mouse hybridoma technology by Kohler and Milstein in 1975, significant progress has been made in monoclonal antibody production. Advances in B cell immortalization and phage display technologies have generated a myriad of valuable monoclonal antibodies for diagnosis and treatment. Technological breakthroughs in various fields of 'omics have shed crucial insights into cellular heterogeneity of a biological system in which the functional individuality of a single cell must be considered. Based on this important concept, remarkable discoveries in single-cell analysis have made in identifying and isolating functional B cells that produce beneficial therapeutic monoclonal antibodies. In this review, we will discuss three traditional methods of antibody discovery. Recent technological platforms for single-cell antibody discovery will be reviewed. We will discuss the application of the single-cell analysis in finding therapeutic antibodies for human immunodeficiency virus and emerging Zika arbovirus.

Keywords: Flow cytometry; Hybridoma; Infectious diseases; Monoclonal antibodies; Single cell.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antibodies, Monoclonal / therapeutic use*
  • Communicable Diseases / drug therapy*
  • Drug Discovery
  • HIV / genetics
  • HIV / physiology
  • HIV Infections / drug therapy*
  • Humans
  • Single-Cell Analysis / methods*
  • Zika Virus / genetics
  • Zika Virus / physiology
  • Zika Virus Infection / drug therapy*
  • Zika Virus Infection / virology

Substances

  • Antibodies, Monoclonal